CRSP3 Rabbit anti-Human, Polyclonal, Bethyl Laboratories
Rabbit Polyclonal Antibody
Manufacturer: Bethyl Laboratories, Inc A300423AT
The recommended shelf life for this product is 1 year from date of receipt. Based on 100% sequence identity, this antibody is predicted to react with Mouse and RatThe activation of gene transcription is a multistep process that is triggered by factors that recognize transcriptional enhancer sites in DNA. These factors work with co-activators to direct transcriptional initiation by the RNA polymerase II apparatus. The protein encoded by this gene is a subunit of the CRSP (cofactor required for SP1 activation) complex, which, along with TFIID, is required for efficient activation by SP1. This protein is also a component of other multisubunit complexes e.g. thyroid hormone receptor-(TR-) associated proteins which interact with TR and facilitate TR function on DNA templates in conjunction with initiation factors and cofactors. This protein also acts as a metastasis suppressor. Two alternatively spliced transcript variants encoding different isoforms have been described for this gene.
|Between 1 and 50|
|Antigen affinity chromatography|
|phosphate, tris citrate with 0.09% sodium azide; pH 7-8|
|Mediator of RNA polymerase II transcription subunit 23, Activator-recruited cofactor 130 kDa component, ARC130, Cofactor required for Sp1 transcriptional activation subunit 3, CRSP complex subunit 3, Mediator complex subunit 23, Protein sur-2 homolog, hSur-2, Transcriptional coactivator CRSP130, Vitamin D3 receptor-interacting protein complex 130 kDa component, DRIP130, MED23, ARC130, CRSP3, DRIP130, KIAA1216, SUR2|
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok